Advances in stroke, a novel antihypertensive, and new evidence that diabetes drugs may offer CVD benefits for those without diabetes are among the top developments in 2023, on the AHA's annual list.
The RNA interference therapeutic targeting synthesis of angiotensinogen lowered BP in adults with mild to moderate hypertension for up to 6 months after one dose in the phase 2 KARDIA-1 study.